Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab
Background: The incidence rate of uveitis in secukinumab-treated patients with axial spondyloarthritis (axSpA) was previously reported. Objective: To evaluate the incidence rate of uveitis in patients with axSpA and psoriatic arthritis (PsA) treated with secukinumab or placebo during placebo-control...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-06-01
|
| Series: | Therapeutic Advances in Musculoskeletal Disease |
| Online Access: | https://doi.org/10.1177/1759720X251340255 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850224739843309568 |
|---|---|
| author | Jan Brandt-Jürgens Martin Rudwaleit Frank Behrens Christopher Ritchlin Daniel Peterlik Erhard Quebe-Fehling Atul Deodhar |
| author_facet | Jan Brandt-Jürgens Martin Rudwaleit Frank Behrens Christopher Ritchlin Daniel Peterlik Erhard Quebe-Fehling Atul Deodhar |
| author_sort | Jan Brandt-Jürgens |
| collection | DOAJ |
| description | Background: The incidence rate of uveitis in secukinumab-treated patients with axial spondyloarthritis (axSpA) was previously reported. Objective: To evaluate the incidence rate of uveitis in patients with axSpA and psoriatic arthritis (PsA) treated with secukinumab or placebo during placebo-controlled phase III studies. Design: This was a post hoc analysis from 11 phase III studies. Methods: Pooled data from axSpA (MEASURE 1–5 and PREVENT studies) and PsA (FUTURE 1–5 studies) were analyzed. Results: In the axSpA cohort ( N = 1980), the incidence rate for uveitis was 1.29 per 100 patient-years in the secukinumab 150 mg and 1.72 per 100 patient-years in the placebo arm. In the PsA cohort ( N = 2453), the incidence rate for uveitis was 0.71 per 100 patient-years in the secukinumab 300 mg arm; no events were reported in the placebo arm. Conclusion: During the placebo-controlled phase, a numerically lower incidence of uveitis was observed in secukinumab-treated axSpA patients. In PsA patients, the incidence was low in secukinumab-treated patients, while uveitis was not reported in the placebo group. |
| format | Article |
| id | doaj-art-2f4ef3ac80cf44e498802c790221dcb5 |
| institution | OA Journals |
| issn | 1759-7218 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Therapeutic Advances in Musculoskeletal Disease |
| spelling | doaj-art-2f4ef3ac80cf44e498802c790221dcb52025-08-20T02:05:32ZengSAGE PublishingTherapeutic Advances in Musculoskeletal Disease1759-72182025-06-011710.1177/1759720X251340255Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumabJan Brandt-JürgensMartin RudwaleitFrank BehrensChristopher RitchlinDaniel PeterlikErhard Quebe-FehlingAtul DeodharBackground: The incidence rate of uveitis in secukinumab-treated patients with axial spondyloarthritis (axSpA) was previously reported. Objective: To evaluate the incidence rate of uveitis in patients with axSpA and psoriatic arthritis (PsA) treated with secukinumab or placebo during placebo-controlled phase III studies. Design: This was a post hoc analysis from 11 phase III studies. Methods: Pooled data from axSpA (MEASURE 1–5 and PREVENT studies) and PsA (FUTURE 1–5 studies) were analyzed. Results: In the axSpA cohort ( N = 1980), the incidence rate for uveitis was 1.29 per 100 patient-years in the secukinumab 150 mg and 1.72 per 100 patient-years in the placebo arm. In the PsA cohort ( N = 2453), the incidence rate for uveitis was 0.71 per 100 patient-years in the secukinumab 300 mg arm; no events were reported in the placebo arm. Conclusion: During the placebo-controlled phase, a numerically lower incidence of uveitis was observed in secukinumab-treated axSpA patients. In PsA patients, the incidence was low in secukinumab-treated patients, while uveitis was not reported in the placebo group.https://doi.org/10.1177/1759720X251340255 |
| spellingShingle | Jan Brandt-Jürgens Martin Rudwaleit Frank Behrens Christopher Ritchlin Daniel Peterlik Erhard Quebe-Fehling Atul Deodhar Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab Therapeutic Advances in Musculoskeletal Disease |
| title | Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab |
| title_full | Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab |
| title_fullStr | Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab |
| title_full_unstemmed | Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab |
| title_short | Uveitis in patients with axial spondyloarthritis or psoriatic arthritis: a post hoc analysis from placebo-controlled phase III studies with secukinumab |
| title_sort | uveitis in patients with axial spondyloarthritis or psoriatic arthritis a post hoc analysis from placebo controlled phase iii studies with secukinumab |
| url | https://doi.org/10.1177/1759720X251340255 |
| work_keys_str_mv | AT janbrandtjurgens uveitisinpatientswithaxialspondyloarthritisorpsoriaticarthritisaposthocanalysisfromplacebocontrolledphaseiiistudieswithsecukinumab AT martinrudwaleit uveitisinpatientswithaxialspondyloarthritisorpsoriaticarthritisaposthocanalysisfromplacebocontrolledphaseiiistudieswithsecukinumab AT frankbehrens uveitisinpatientswithaxialspondyloarthritisorpsoriaticarthritisaposthocanalysisfromplacebocontrolledphaseiiistudieswithsecukinumab AT christopherritchlin uveitisinpatientswithaxialspondyloarthritisorpsoriaticarthritisaposthocanalysisfromplacebocontrolledphaseiiistudieswithsecukinumab AT danielpeterlik uveitisinpatientswithaxialspondyloarthritisorpsoriaticarthritisaposthocanalysisfromplacebocontrolledphaseiiistudieswithsecukinumab AT erhardquebefehling uveitisinpatientswithaxialspondyloarthritisorpsoriaticarthritisaposthocanalysisfromplacebocontrolledphaseiiistudieswithsecukinumab AT atuldeodhar uveitisinpatientswithaxialspondyloarthritisorpsoriaticarthritisaposthocanalysisfromplacebocontrolledphaseiiistudieswithsecukinumab |